Beyond their antihyperglycemic effects, SGLT-2 inhibitors exhibit potential cardiovascular and metabolic benefits, rendering them compelling options for the therapeutic management of PCOS [35]. This evidence concerns the gene SLC5A2 and polycystic ovary syndrome.